MacroGenics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Good morning everybody, Thank you so much for joining the Credit Suisse 30th Annual Healthcare Conference. This is John Hoffman from ECM team speaking, pleasure to have you all here today. I'm joined this morning by Scott Koenig, CEO of MacroGenics regarding the corporate update. Scott, I'd like to turn the floor over to you.
Thank you very much, John. Thank you for the opportunity to present at the Credit Suisse conference. I'll be making forward-looking statements during my presentation so please refer to our SEC filings to understand the risks investing in MacroGenics. 2021 was the year of significant advancement for MacroGenics, we launched MARGENZA our first in-house develop proprietory product with our partner EVERSANA in March. We advanced our B7-H3 portfolio and continue to demonstrate the value of our technology platforms which include our bispecific DART technology, our Fc Optimization platform and our ADC-based antibody molecules. Out of 9 molecules in clinical development we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
